OUR APPROACH

Six programmes, grouped by virus family

Influenza

Supra-Seasonal Influenza

DVX-Supra Seasonal
Designed for influenza beyond a single season.

Modality: mRNA

The challenge

Flu strains are chosen months before the season and the vaccine is made to match them. But the virus keeps evolving. Seasonal vaccine effectiveness varies, and protection can fall further when circulating strains no longer match the vaccine.

Current seasonal vaccines

  1. Strain selectionStrains selected ahead of the coming season.
  2. Wild-type antigenBased on selected circulating strains.
  3. One seasonReformulated and administered annually.
  4. Variable protectionEffectiveness can fall further with vaccine mismatch.

Seasonal effectiveness is low, variable and falls further on mismatch

US adjusted vaccine effectiveness by season, 2010–11 to 2025–26

Gold highlights the 2014–15 H3N2 drift season. Values are percentages.

  1. 2010–1160%
  2. 2011–1247%
  3. 2012–1349%
  4. 2013–1452%
  5. 2014–1519%
  6. 2015–1648%
  7. 2016–1740%
  8. 2017–1838%
  9. 2018–1929%
  10. 2019–2039%
  11. 2020–21Not estimated
  12. 2021–2236%
  13. 2022–2330%
  14. 2023–2444%
  15. 2024–25*56%
  16. 2025–26*36%
Source: adapted from CDC seasonal flu vaccine effectiveness studies (opens in a new tab). No estimate for 2020–21 because influenza circulation was too low during the COVID-19 pandemic. *2024–25 and 2025–26 estimates are preliminary.
Low

No season shown exceeded 60% effectiveness.

Variable

Effectiveness varied more than threefold across the seasons shown.

Fragile

Effectiveness fell to 19% in the 2014–15 H3N2 drift season.

Our approach

Rather than copying the strains predicted for one season, DIOSynVax designs antigens using the evolutionary history of influenza. The aim is broader seasonal coverage that lasts beyond a single season.

“Supra-seasonal” describes this intended coverage beyond one season. Seasonal vaccines are matched each year to selected strains; a universal influenza vaccine would aim to cover both seasonal and pandemic strains.

Antigen design

The multi-target design combines engineered antigens directed at surface and internal viral proteins. It is designed to engage both antibody and T-cell responses: antibodies against surface targets to help block infection, and T cells against internal targets to help clear infected cells.

Preclinical evidence: ferret model

  • Approximately 90% versus approximately 24% of a diverse panel of swine, seasonal and pandemic H1 strains neutralised, compared with a licensed adjuvanted seasonal vaccine. This measures the breadth of neutralisation, not vaccine efficacy.
  • 38% versus 8% reduction in disease burden after H1N1 challenge, relative to unvaccinated animals.
  • Day 6: viral shedding at the limit of detection after challenge.

Preclinical data from controlled ferret challenge studies conducted by an external laboratory. Results may not predict outcomes in humans.

Development status

Preclinical complete · preparing Phase 1/2a · open to partnering.

Talk to us about partnering

Preclinical complete · preparing Phase 1/2a

Modality: mRNA
Avian Influenza (pan-H5)

Preclinical complete

Modality: mRNA
Universal Influenza

Preclinical complete

Modality: mRNA

Coronavirus

Pan-Sarbecovirus

Phase I complete (pEVAC-PS, J Infect 2026)

Modality: DNA
Pan-Beta-Coronavirus

Preclinical complete

Modality: mRNA

Viral Haemorrhagic Fever

TriLFMvac (Lassa, Ebola, Marburg)
Modality: MVA